Get the Stockscreener App
30.43
8.18%
-2.71
Beam Therapeutics Inc stock is traded at $30.43, with a volume of 1.88M.
It is down -8.18% in the last 24 hours and up +24.05% over the past month.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
See More
Previous Close:
$33.14
Open:
$33.91
24h Volume:
1.88M
Relative Volume:
1.61
Market Cap:
$2.52B
Revenue:
$352.57M
Net Income/Loss:
$-143.01M
P/E Ratio:
-16.81
EPS:
-1.81
Net Cash Flow:
$-153.40M
1W Performance:
-6.08%
1M Performance:
+24.05%
6M Performance:
+19.38%
1Y Performance:
-4.19%
1-Day Range:
$30.19
$33.91
1-Week Range:
$30.19
$35.25
52-Week Range:
$20.84
$49.50
Beam Therapeutics Inc Stock (BEAM) Company Profile
Name
Beam Therapeutics Inc
Sector
Industry
Phone
857-327-8775
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
30.43 | 2.52B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-23-24 | Initiated | H.C. Wainwright | Buy |
| Jan-29-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-08-23 | Downgrade | Jefferies | Buy → Hold |
| Oct-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-20-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-13-22 | Initiated | Citigroup | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Jan-05-22 | Initiated | Guggenheim | Buy |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Sep-24-21 | Resumed | Stifel | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Redburn | Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-16-21 | Initiated | Wells Fargo | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Aug-05-20 | Initiated | William Blair | Outperform |
| Mar-02-20 | Initiated | Barclays | Overweight |
| Mar-02-20 | Initiated | JP Morgan | Overweight |
| Mar-02-20 | Initiated | Jefferies | Buy |
| Mar-02-20 | Initiated | Wedbush | Outperform |
View All
Beam Therapeutics Inc Stock (BEAM) Latest News
Cathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive Biotechnologies - Benzinga India
C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Takes $330,000 Position in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics (BEAM) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Cathie Wood’s ARK buys Beam Therapeutics, sells Adaptive Biotech stock By Investing.com - Investing.com Nigeria
Cathie Wood's ARK buys Beam Therapeutics, sells Adaptive Biotech stock - Investing.com India
Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Significant Decline in Short Interest - MarketBeat
Baillie Gifford & Co. Cuts Position in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Peregrine Investment Management Inc. Takes $3.93 Million Position in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Stock Price Up 17.9%Here's What Happened - MarketBeat
Cathie Wood's ARK ETF adds Twist Bioscience, Beam Therapeutics stock By Investing.com - Investing.com Australia
Cathie Wood's ARK ETF adds Twist Bioscience, Beam Therapeutics stock - Investing.com
Cathie Wood’s ARK ETF adds Twist Bioscience, Beam Therapeutics stock By Investing.com - Investing.com Nigeria
Next Generation Genome Editing Market Top Companies Study - openPR
C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Buys Shares of 13,287 Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics to present updated BEAM-101 trial data - MSN
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
(BEAM) Technical Data - Stock Traders Daily
Cathie Wood's Ark Invest Loads Up On Iridium, Twist Bioscience, Offloads Roku: Here Are Key Ark Trades This Friday - Benzinga
Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday - Benzinga
Wall Street Analysts See a 67.27% Upside in Beam Therapeutics (BEAM): Can the Stock Really Move This High? - Yahoo Finance
Is Beam Therapeutics (BEAM) Outperforming Other Medical Stocks This Year? - MSN
Sumitomo Mitsui Trust Group Inc. Acquires 404,782 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics (BEAM) Stock Price, News & Analysis - MarketBeat
BMO Capital maintains Outperform on Beam Therapeutics stock By Investing.com - Investing.com Nigeria
BMO Capital maintains Outperform on Beam Therapeutics stock - MSN
Beam Therapeutics (NASDAQ:BEAM) Trading 8% HigherShould You Buy? - MarketBeat
FY2026 Earnings Estimate for BEAM Issued By HC Wainwright - MarketBeat
Brokers Issue Forecasts for BEAM Q1 Earnings - MarketBeat
HC Wainwright Reiterates "Buy" Rating for Beam Therapeutics (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) CEO Sells $802,500.00 in Stock - MarketBeat
Beam Therapeutics Inc Stock (BEAM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Beam Therapeutics Inc Stock (BEAM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bellon Christine | Chief Legal Officer |
Feb 14 '25 |
Option Exercise |
7.22 |
10,000 |
72,200 |
112,968 |
| Bellon Christine | Chief Legal Officer |
Feb 14 '25 |
Sale |
34.00 |
10,000 |
340,000 |
102,968 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):